The mission of our clinical research is to foster discoveries in the novel therapies of inflammatory bowel diseases, gastrointestinal and pancreatic cancer, hepatitis, and other gastrointestinal disorders. Our doctors are committed to providing the best care and management of diseases while testing cutting-edge therapies.

Back to full list of clinical trials

Ongoing clinical trials for non-alcoholic steatohepatitis: Actively recruiting


Condition:

Non-alcoholic steatohepatitis

Study title:

A Phase 2b, Dose-Ranging, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Safety and Efficacy of GS-6624, a Monoclonal Antibody Against Lysyl Oxidase-Like 2 (LOXL2), in Subjects with Advanced Liver Fibrosis but not Cirrhosis Secondary to Non-Alcoholic Steatohepatitis (NASH)

Description of study:

The goal of this study is to see if the monoclonal antibody, GS-6624 is effective at preventing the progression of liver fibrosis in people with NASH.

Basic eligibility criteria:

Adults aged 18-65 with NASH; willing to commit to a 2 year study with visits twice a month. Clinical Trials.gov identifier: NCT01672866

Principal Investigator:

Kathleen Corey, MD, MPH

Contact:

Jenna Gustafson: 617-724-3836 and Kyle Malecki: 617-726-3670


Condition:

Non-alcoholic steatohepatitis

Study title:

A Phase 2b, Dose-Ranging, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Safety and Efficacy of GS-6624, a Monoclonal Antibody Against Lysyl Oxidase-Like 2 (LOXL2), in Subjects with Compensated Cirrhosis Secondary to Non-Alcoholic Steatohepatitis (NASH)

Description of study:

The goal of this study is to see if the monoclonal antibody, GS-6624 is effective at reversing liver scarring and heal cirrhosis in people with NASH.

Basic eligibility criteria:

Adults aged 18-65 with NASH and cirrhosis; willing to commit to a 2 year study with visits twice a month; Clinical Trials.gov identifier: NCT01672879

Principal Investigator:

Kathleen Corey, MD, MPH

Contact:

Jenna Gustafson: 617-724-3836 and Kyle Malecki: 617-726-3670